EVIDENCE LIBRARY
Did Equimolar Prodrugs Produce Equal Plasma Psilocin Exposure in Mice?
Administering equimolar amounts of two prodrugs does not guarantee equal exposure to their shared active metabolite. Jones and colleagues tested that distinction for psilacetin fumarate and psilocybin in mice.
The measured compound was psilocin
The investigators administered the prodrugs by intraperitoneal injection to male and female C57Bl6/J mice. They used LC–MS/MS to quantify psilocin in plasma collected at specified times after administration.
The specimens came from terminal collections, and no mouse was reused for another injection. The resulting time courses therefore should not be described as repeated blood measurements following the same individual through every sampling time.
Similar elimination did not mean equal exposure
The study reported a psilocin half-life of approximately 30 minutes after either prodrug. Nevertheless, psilacetin fumarate produced lower peripheral psilocin exposure. The authors estimated relative exposure at approximately 70% of that obtained from psilocybin using their dose-normalized area comparisons.
Half-life describes one aspect of the concentration-time pattern. It is not a substitute for the amount of exposure represented by the area under that pattern. Keeping both results avoids treating a similar disappearance rate as proof that the complete profiles were identical.
The comparison has defined boundaries
Equimolar dosing controls the administered molecular amount being compared. Conversion, distribution and elimination still determine the measured metabolite profile. The study directly supports psilocin formation from psilacetin in this animal model.
It does not establish equal subjective potency, a human substitution ratio or equivalent exposure after oral administration. Those questions require evidence about the relevant species, route, formulation and outcomes rather than a direct transfer of this mouse plasma comparison.
Source: Jones NT et al. (2024). In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. DOI: 10.3389/fpsyt.2023.1303365.